{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T19:35:38Z","timestamp":1783625738758,"version":"3.55.0"},"reference-count":34,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The inv(16) cytogenetic subtype of acute myeloid leukemia (AML) has a relatively good prognosis. Many patients achieve complete remission (CR). The prognostic uncertainty of negative qualitative reverse transcription\u2013polymerase chain reaction (RT-PCR) assays suggests the need to identify prognostically significant critical thresholds by real-time RT-PCR. A reliable and sensitive (10\u22125) real-time RT-PCR assay was set up for the evaluation of relevant CBF\u03b2-MYH11\/ABL transcript ratios and was applied to the 21 patients with inv(16) AML routinely referred for cytogenetic and molecular monitoring in Sera\u0300gnoli Institute (Bologna, Italy) since 1990. Among the 18 patients who underwent ablative chemotherapy, all achieved CR with a 3-year disease-free survival probability of 63% (95% CI, 40%-87%) and no recorded events after 26 months. Five patients had relapses; 2 died of disease and 3 entered second CR. Analysis of the 125 bone marrow (or peripheral blood) samples studied by real-time RT-PCR showed that transcript ratios of samples taken during CR at any time before a relapse were always greater than 0.12%, whereas those of samples taken during first or second CR from patients who did not subsequently have relapses were always less than 0.25%. This suggests that transcript ratios greater than 0.25% may correspond to high risk for relapse, whereas ratios below 0.12% might indicate the patient is in a curable state. If confirmed, such thresholds could open the way to a new phase in post-CR therapeutic decision making for patients with inv(16) AML.<\/jats:p>","DOI":"10.1182\/blood.v99.2.443","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T12:46:47Z","timestamp":1027774007000},"page":"443-449","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":122,"title":["Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state"],"prefix":"10.1182","volume":"99","author":[{"given":"Silvia","family":"Buonamici","sequence":"first","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology L. e A. Sera\u0300gnoli, University of Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Ottaviani","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology L. e A. Sera\u0300gnoli, University of Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Testoni","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology L. e A. Sera\u0300gnoli, University of Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Montefusco","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology L. e A. Sera\u0300gnoli, University of Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Visani","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology L. e A. Sera\u0300gnoli, University of Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bonifazi","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology L. e A. Sera\u0300gnoli, University of Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilina","family":"Amabile","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology L. e A. Sera\u0300gnoli, University of Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Terragna","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology L. e A. Sera\u0300gnoli, University of Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Ruggeri","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology L. e A. Sera\u0300gnoli, University of Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Paolo","family":"Piccaluga","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology L. e A. Sera\u0300gnoli, University of Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Isidori","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology L. e A. Sera\u0300gnoli, University of Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Malagola","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology L. e A. Sera\u0300gnoli, University of Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Baccarani","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology L. e A. Sera\u0300gnoli, University of Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sante","family":"Tura","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology L. e A. Sera\u0300gnoli, University of Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[{"name":"From the Institute of Hematology and Medical Oncology L. e A. Sera\u0300gnoli, University of Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021217164458200_B1","first-page":"122","article-title":"Recurring chromosome abnormalities in leukemia and lymphoma.","volume":"27","author":"Rowley","year":"1990","journal-title":"Semin Hematol."},{"key":"2020021217164458200_B2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/gcc.2870030110","article-title":"Chromosome 16 abnormalities associated with myeloid malignancies.","volume":"3","author":"Campbell","year":"1991","journal-title":"Genes Chromosomes Cancer."},{"key":"2020021217164458200_B3","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJM198309153091103","article-title":"Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia.","volume":"309","author":"LeBeau","year":"1983","journal-title":"N Engl J Med."},{"key":"2020021217164458200_B4","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1126\/science.8351518","article-title":"Fusion between transcription factor CBF\u03b2\/PEBP2\u03b2 and a myosin heavy chain in acute myeloid leukemia.","volume":"261","author":"Liu","year":"1993","journal-title":"Science."},{"key":"2020021217164458200_B5","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/0145-2126(94)90098-1","article-title":"Inv(16) may be one of the only favorable factors in acute myeloid leukemia: a report on 19 cases with prolonged follow-up.","volume":"18","author":"Plantier","year":"1994","journal-title":"Leuk Res."},{"key":"2020021217164458200_B6","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1182\/blood.V68.6.1242.1242","article-title":"Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis.","volume":"68","author":"Larson","year":"1986","journal-title":"Blood."},{"key":"2020021217164458200_B7","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1182\/blood.V82.3.716.716","article-title":"Identification of yeast artificial chromosomes containing the inversion 16 p-arm breakpoint associated with acute myelomonocytic leukemia.","volume":"82","author":"Liu","year":"1993","journal-title":"Blood."},{"key":"2020021217164458200_B8","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1006\/viro.1993.1262","article-title":"Molecular cloning and characterization of PEBp2b: the heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2a.","volume":"194","author":"Ogawa","year":"1993","journal-title":"Virology."},{"key":"2020021217164458200_B9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ajmg.1320460110","article-title":"Human smooth muscle myosin heavy chain gene mapped to chromosomal region 16q12.","volume":"46","author":"Matsuoka","year":"1993","journal-title":"Am J Med Genet."},{"key":"2020021217164458200_B10","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1006\/geno.1993.1443","article-title":"Smooth muscle myosin heavy chain locus (MYH11) maps to 16p13.3-p13.12 and establishes a new region of conserved synteny between human 16p and mouse 16.","volume":"18","author":"Deng","year":"1993","journal-title":"Genomics."},{"key":"2020021217164458200_B11","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1182\/blood.V83.7.1750.1750","article-title":"Detection of fusion transcript generated by the inversion 16 chromosome in acute myelogenous leukemia.","volume":"83","author":"Claxton","year":"1994","journal-title":"Blood."},{"key":"2020021217164458200_B12","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1182\/blood.V90.12.5022b","article-title":"Defining the \u201cabsence\u201d of the CBF\u03b2-MYH11 fusion transcripts in patients with acute myeloid leukemia and inversion of chromosome 16 to predict long term complete remission: a call for definition [letter].","volume":"90","author":"Marcucci","year":"1997","journal-title":"Blood."},{"key":"2020021217164458200_B13","doi-asserted-by":"crossref","first-page":"7276","DOI":"10.1073\/pnas.88.16.7276","article-title":"Detection of specific polymerase chain reaction product by utilizing the 5'\u21923' exonuclease activity of Thermus aquaticus DNA polymerase.","volume":"88","author":"Holland","year":"1991","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2020021217164458200_B14","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1046\/j.1365-2141.1998.00823.x","article-title":"Quantitation of minimal residual disease in Philadelphia chromosome-positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR.","volume":"102","author":"Mensink","year":"1998","journal-title":"Br J Haematol."},{"key":"2020021217164458200_B15","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/sj.leu.2401652","article-title":"Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR.","volume":"14","author":"Cassinat","year":"2000","journal-title":"Leukemia."},{"key":"2020021217164458200_B16","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/sj.leu.2401128","article-title":"Detection of minimal residual disease in patients with AML1\/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay.","volume":"12","author":"Marcucci","year":"1998","journal-title":"Leukemia."},{"key":"2020021217164458200_B17","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/sj.bmt.1701963","article-title":"Molecular remission in PCR-positive acute myeloid leukemia patients with inv(16): role of bone marrow transplantation procedures.","volume":"24","author":"Martinelli","year":"1999","journal-title":"Bone Marrow Transplant."},{"key":"2020021217164458200_B18","first-page":"552","article-title":"Long-term disease-free acute myeloblastic leukemia with inv(16) is associated with PCR undetectable CBF\u03b2\/MYH11 transcript.","volume":"85","author":"Martinelli","year":"2000","journal-title":"Haematologica."},{"key":"2020021217164458200_B19","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2141.1995.tb05253.x","article-title":"Detection of CBFB\/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission.","volume":"91","author":"Tobal","year":"1995","journal-title":"Br J Haematol."},{"key":"2020021217164458200_B20","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1182\/blood.V89.6.2222","article-title":"Prognosis value of residual disease monitoring by polymerase chain reaction in patients with CBF\u03b2\/MYH11 positive acute myeloblastic leukemia [letter].","volume":"89","author":"Costello","year":"1997","journal-title":"Blood."},{"key":"2020021217164458200_B21","first-page":"333","article-title":"RT-PCR monitoring of CBF\u03b2\/MYH11 in patients with AML and chromosomal inv(16): variable behavior of the chimeric mRNA during treatment [abstract].","volume":"84","author":"Novak","year":"1995","journal-title":"Blood."},{"key":"2020021217164458200_B22","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","article-title":"Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease.","volume":"13","author":"Van Dongen","year":"1999","journal-title":"Leukemia."},{"key":"2020021217164458200_B23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of acute leukaemias.","volume":"33","author":"Bennett","year":"1977","journal-title":"Br J Haematol."},{"key":"2020021217164458200_B24","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/sj.bmt.1701491","article-title":"Autologous peripheral blood stem cells transplantation is acute myeloblastic leukaemia and myelodysplastic syndrome patients: evaluation of tumour cell contamination of leukaphereses by cytogenetic and molecular methods.","volume":"22","author":"Testoni","year":"1998","journal-title":"Bone Marrow Transplant."},{"key":"2020021217164458200_B25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation for incomplete observation.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc."},{"key":"2020021217164458200_B26","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1182\/blood.V85.12.3695.bloodjournal85123695","article-title":"Heterogeneity in CBF\u03b2\/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia.","volume":"85","author":"Shurtleff","year":"1995","journal-title":"Blood."},{"key":"2020021217164458200_B27","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/sj.leu.2400578","article-title":"Detection and quantification of the transcript associated with the inv(16) in presentation and follow-up samples from patients with AML.","volume":"11","author":"Evans","year":"1997","journal-title":"Leukemia."},{"key":"2020021217164458200_B28","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood.V95.3.815.003k30_815_819","article-title":"Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse.","volume":"95","author":"Tobal","year":"2000","journal-title":"Blood."},{"key":"2020021217164458200_B29","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1046\/j.1365-2141.1997.3933207.x","article-title":"Successful collection of peripheral blood progenitor cells in patients with acute myeloid leukaemia following early consolidation therapy with granulocyte colony-stimulating factor-supported high-dose cytarabine and mitoxantrone.","volume":"99","author":"Schlenk","year":"1997","journal-title":"Br J Haematol."},{"key":"2020021217164458200_B30","first-page":"82","article-title":"Remission induction therapy for adults with acute myelogenous leukemia: towards the ICE age?","volume":"80","author":"Bassan","year":"1995","journal-title":"Haematologica."},{"key":"2020021217164458200_B31","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3109\/10428199509112203","article-title":"MEC (mitoxantrone, etoposide and intermediate dose cytarabine): an effective induction regimen for previously untreated acute non-lymphocytic leukemia.","volume":"19","author":"Visani","year":"1995","journal-title":"Leuk Lymphoma."},{"key":"2020021217164458200_B32","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/sj.bmt.1701920","article-title":"Use of peripheral blood stem cell for autologous transplantation acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.","volume":"24","author":"Visani","year":"1999","journal-title":"Bone Marrow Transplant."},{"key":"2020021217164458200_B33","first-page":"513","article-title":"High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia.","volume":"81","author":"Clavio","year":"1996","journal-title":"Haematologica."},{"key":"2020021217164458200_B34","first-page":"1842","article-title":"FLANG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of \u201cpoor risk\u201d acute myeloid leukemias.","volume":"8","author":"Visani","year":"1994","journal-title":"Leukemia."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/99\/2\/443\/1679781\/h8020200443.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/99\/2\/443\/1679781\/h8020200443.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T09:30:20Z","timestamp":1622021420000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/99\/2\/443\/53381\/Realtime-quantitation-of-minimal-residual-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1,15]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,1,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v99.2.443","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2002,1,15]]}}}